Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCaitlin R. RauschNPNaveen PemmarajuGGGuillermo Garcia‐Manero

Discussion

Loading...

Member takes

Overview

Propensity score analysis shows improved survival outcomes in adults with acute lymphoblastic leukemia treated with hyper-CVAD plus blinatumomab, suggesting favorability of this regimen.

Key Points

  • Blinatumomab significantly improves survival outcomes in patients with acute lymphoblastic leukemia.
  • Patients receiving hyper-CVAD and blinatumomab showed higher rates of measurable residual disease negativity.
  • Utilizing propensity score matching, treatment outcomes were better for those on hyper-CVAD plus blinatumomab.
  • This analysis reinforces the need for ongoing randomized trials to validate these findings.

Cite This Study

Rausch et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de6ehttps://doi.org/10.1182/blood-2025-1566
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab2025 · 1 citations
  2. 2Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens2025
  3. 3The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study2025 · 2 citations
  4. 4Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL17312025
  5. 5Real-world administration blinatumomab in the outpatient setting: Toxicity outcomes and healthcare utilization2025